Atea Pharmaceuticals Inc. Aktie

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to the discovery, development, and commercialization of antiviral treatments for patients with viral infections. Its primary investigational drug, AT-527, is an antiviral currently undergoing Phase II clinical trials for the treatment of COVID-19. Beyond its lead candidate, Atea's development pipeline encompasses a range of other drug candidates. These include AT-752, an oral purine nucleoside prodrug that has completed Phase Ia clinical trials for dengue, and AT-777, an NS5A inhibitor. Atea is also advancing AT-787, which is a co-formulated, oral, pan-genotypic fixed-dose combination of AT-527 and AT-777 designed for hepatitis C virus (HCV) treatment. Additionally, AT-281, a pharmaceutically acceptable salt, is under investigation for its potential to treat or prevent RNA viral infections such as dengue fever, yellow fever, Zika virus, and coronaviridae. The company's portfolio further comprises Ruzasvir, an investigational oral, pan-genotypic NS5A inhibitor for chronic HCV infection. Atea maintains a license agreement with Merck & Co, Inc. for the development and commercialization of ruzasvir for HCV treatment. Established in 2012, Atea Pharmaceuticals, Inc. operates from its headquarters in Boston, Massachusetts.